Business Wire

“Travel and tourism builds diversified and resilient economies”: Saudi Arabia Minister of Tourism, His Excellency Ahmed Al-Khateeb, tells World Economic Forum Annual Meeting in Davos

24.1.2025 20:59:00 CET | Business Wire | Press release

Share

Official Travel & Tourism sessions were prominently featured on the WEF agenda, with global leaders unpacking the transformative power of the sector. His Excellency urged global leaders to give the sector the attention it deserves to catalyze sustainable, cross-border, multi-sector economic growth.

The Travel and Tourism sector’s essential contribution to shaping the global landscape was underscored at the World Economic Forum (WEF) Annual Meeting in Davos this week with His Excellency Ahmed A. Al-Khateeb, Saudi Arabia Minister of Tourism, urging world leaders to provide the industry with the focus and collaborative solutions it deserves.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124536028/en/

Saudi Minister of Tourism, His Excellency Ahmed A. Al-Khateeb put travel and tourism on the global agenda at the World Economic Forum Annual Meeting in Davos, Switzerland, this week. (Photo: AETOSWire)

Saudi Arabia welcomed nearly 30 million international visitors in 2024 and contributed almost 5% to the Kingdom’s GDP. In dedicated WEF sessions on travel and tourism, His Excellency, who attended Davos as part of the official Saudi Arabia WEF Delegation, highlighted the Kingdom’s unprecedented growth rates. He stressed the critical role that tourism has in building diversified and resilient economies, emphasizing that when Saudi Vision 2030 unlocked the travel and tourism sector, the Kingdom began building a holistic tourism experience based on international collaboration, best practices, and sustainable development.

As the WEF Annual Meeting concluded, His Excellency noted that the world was watching the remarkable resurgence of tourism, with the industry now fully recovered to pre-pandemic levels with 1.4 billion international arrivals in 2024.

“The world is counting on us to build a vibrant tourism ecosystem that meets growing demand while safeguarding our planet and quality of life. Tourism is more than an industry - it is a transformative force. We need to foster collective action to balance economic growth in the industry with social and environmental responsibility and ensuring the sector's resilience,” His Excellency said.

Throughout the forum, His Excellency led discussions as a key voice on official WEF panels including "Travel and Tourism’s Role in Building Trust” and "The Way We Will Travel”, focused on mobilizing diversified sector growth and enhancing global collaboration to propel the travel and tourism sector to keep up with growing demand, as well as a high-level session at Saudi House that explored “Scaling Sustainable Tourism: Connecting People and Places.”

He shared the stage with distinguished leaders, including Albania Prime Minister Edi Rama, European Commissioner for Transport and Tourism Apostolos Tzitzikostas, Switzerland Tourism CEO Martin Nydegger and Trip.com CEO Jane Sun who all shared His Excellency’s sentiment on the need for further global collaboration.

In alignment with Saudi Arabia’s forward-thinking tourism strategy, the Ministry launched a new investment guide, the "Hospitality Investor White Paper" during the WEF Annual Meeting. This initiative supports Vision 2030's ambitious targets, aiming to attract more than SAR 40 billion (USD 11 billion) in private investments, contribute SAR 16 billion (USD 4 billion) to the GDP, and create 1.6 million jobs by 2030.

Minister Al-Khateeb also contributed expert insights to the WEF’s "The Future of Travel and Tourism: Embracing Sustainable and Inclusive Growth” briefing paper highlighting the growing demand for sustainable travel and the importance of cross-sector collaboration and the need to ensure local communities globally benefit from the resulting growth.

As the WEF Annual Meeting concludes, Minister Al-Khateeb's participation underscores Saudi Arabia's transformative role in reshaping the global tourism landscape, reinforcing the Kingdom's vision to establish itself as a leading hub for sustainable travel.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124536028/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye